Prediction of survival and outcomes with depth of response at 6 months in metastatic non-small-cell lung cancer patients treated with chemotherapy and immunotherapy combination: SPORE trial
Depth of response at 6 months according to RECIST 1.1 criteria for patients with mNSCLC still on first-line therapy is a predictor of overall survival.
Authors
- Julie Lasvergnas (ORCID: https://orcid.org/0000-0003-2928-1988)
- Olivier Bylicki (ORCID: https://orcid.org/0000-0001-8683-0969)
- G. Justeau (ORCID: https://orcid.org/0000-0002-2137-113X)
- H. Le Floch
- J-B. Barbe-Richaud
- Julien Ancel
- C. Chouaid
- R. Schott
- F. Moinard-Butot
Institutions
- Twitter (United States) (US)
- Institut de Cancérologie Strasbourg (FR)
- Centre Hospitalier Universitaire de Reims (FR)
- Hôpital d'instruction des Armées Percy (FR)
- Hôpital Intercommunal de Créteil (FR)
- Université d'Angers (FR)
- Université de Reims Champagne-Ardenne (FR)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-01-29
- DOI
- https://doi.org/10.1016/j.esmoop.2025.106042
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00